Information about contact transmission from the MILVAX-VHCN Clinical Services clinical staff.
Contact Transmission Presentation (pdf)
Clinical Guide to diagnosis and treating contact transmission
Contact Transmission Algorithm (pdf)
Smallpox vaccine contains live vaccinia virus. When a person receives smallpox vaccine, the live vaccinia virus replicates and is shed
at the vaccination site. Unintended transmission of vaccinia virus from a vaccine recipient (vaccinee) to an unvaccinated person (contact)
is known as contact transmission, contact vaccinia, or secondary transmission. Contact transmission results when vaccinia virus spreads from
a vaccination site to another person. Inadvertent transmission can occur as early as two days after vaccination up until the time when the
skin under the vaccination site scab returns to its pre-vaccination state. The lesions that result from contact transmission usually resemble
the vaccinee's smallpox vaccination site. Contacts also may experience minor vaccine-related symptoms, e.g., fever, lymphadenopathy, headache
and body aches. Certain groups of persons who experience contact transmission are at risk for more serious adverse reactions.
The vaccinia virus can be transmitted through direct contact with the vaccination site or fluid from the site, and can also be indirectly
transmitted through contact with fomites (e.g., towels, linen). No data supports vaccinia transmission occurring through aerosolization or
transmission through saliva or seminal fluids. The vaccinia virus cannot be spread once the skin under the vaccination site scab returns to
its pre-vaccination state (i.e., the skin under the scab looks like the skin surrounding the vaccination site.)
The risk of contact transmission is very low if vaccinees and their contacts follow proper vaccination-site care and handwashing technique.
The risk of contact transmission is higher for primary vaccinees than for revaccinees. The risk of serious adverse events from contact transmission
is increased in persons with the following conditions:
The DoD Smallpox Vaccination Program was initiated in December 2002. Between December 2002 and January 2004, the reported rate of contact
transmission was 5 per 100,000. Between February 2004 and May 2009 the reported rate of contact transmission was also 5 per 100,000.
These rates from the current DoD program are similar to overall contact transmission rates during mass immunization programs in the 1950s
and 1960s in the range of 2-6/100,000 vaccinations.
Within DoD-reported contact vaccinia cases, the primary mode of transmission has been through very close contact between the vaccinee and
the contact, with a majority of the contacts described as intimate and the second most common type of contact described as sports-related (e.g., wrestling, basketball).
Reports of serious reactions in cases of contact transmission:
In patients being evaluated for recently appearing lesion(s) compatible with vaccinia infection (e.g., vesicular-pustular lesions):
Possible cases of contact transmission should be reported to the Vaccine Adverse Event Reporting System.
To request clinical consultation and/or to have patient entered in the MILVAX-VHCN Clinical Services
Smallpox Contact Transmission Registry, contact the MILVAX-VHCN Clinical Services
at 1-866-210-6469 or
Barkdoll TW, Cabiad RB, Tankersley MS, et al. Secondary and tertiary transfer of vaccinia virus among U.S.
military personnel-United States and worldwide, 2002-2004. MMWR.2004;53(Feb 13):103-105.
CDC. Household transmission of vaccinia virus from contact with military smallpox vaccinee--Illinois and Indiana, 2007.
MMWR Morb Mortal Wkly Rep. May 18 2007;56(19):478-481.
CDC. Vulvar vaccinia infection after sexual contact with a military smallpox vaccinee--Alaska, 2006.
MMWR Morb Mortal Wkly Rep. May 4 2007;56(17):417-419.
CDC. Women with smallpox vaccine exposure during pregnancy reported to the National Smallpox Vaccine in Pregnancy
Registry - United States, 2003. MMWR Morb Mortal Wkly Rep. May 2, 2003;52(17):386-388.
Cummings JF, Polhemus ME, Hawkes C, Klote M, et al. Persistence of vaccinia at the site of smallpox vaccination. Clin Inf Dis. 2008;46:000.
Hammarlund E, Lewis MW, Hanifin JM, Simpson EL, Carlson NE, Slifka MK. Traditional smallpox vaccination with reduced risk of
inadvertent contact spread by administration of povidone iodine ointment. Vaccine. 2008 Jan 17;26(3):430-9
Lederman E, Miramontes R, Openshaw J, Olsen VA, Karem KL, et al. Eczema vaccinatum resulting from the transmission of vaccinia virus from a
smallpox vaccine: An investigation of potential fomites in the home environment. Vaccine. Jan 14 2009;27(3):375.
Napolitano PG, Ryan MA, Grabenstein JD. Pregnancy discovered after smallpox vaccination: Is vaccinia immune globulin appropriate? Am J Obstet Gynecol. Dec 2004;191(6):1863-1867.
Savona MR, Cruz WP, Thornton JA, Danaher PJ. Comparison of a semipermeable dressing bonded to an absorbent pad and a semipermeable
dressing over a separate gauze pad for containment of vaccinia virus at the vaccination site. Infect Control Hosp Epidemiol. Dec 2007;28(12):1339-1343.
Stark JH, Frey SE, Blum PS, Monath TP. Lack of transmission of vaccinia virus. Emerg Infect Dis. Apr 2006;12(4):698-700.
Talbot TR, Peters J, Yan L, Wright PF, Edwards KM. Optimal bandaging of smallpox vaccination sites to decrease the potential
for secondary vaccinia transmission without impairing lesion healing. Infect Control Hosp Epidemiol. Nov 2006;27(11):1184-1192.
Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccine. Clin Infect Dis. 2008 May 15; 46(10):1555-61.
Lewis FS, Norton SA, Bradshaw RD, Lapa J, Grabenstein JD. Analysis of cases reported as generalized vaccinia during the US military smallpox
vaccination program, December 2002 to December 2004. J Am Acad Dermatol. 2006 Jul;55(1):23-31.